Loading...
Loading...
IMTX| Name | Value |
|---|---|
| Revenues | 30.4M |
| Cost of Revenue | 32.1M |
| Gross Profit | -1.7M |
| Operating Expense | 41.0M |
| Operating I/L | -13.6M |
| Other Income/Expense | 11.8M |
| Interest Income | 6.3M |
| Pretax | -1.7M |
| Income Tax Expense | 1.3M |
| Net Income/Loss | -3.1M |
Immatics N.V. is a clinical-stage biopharmaceutical company specializing in T cell receptor (TCR) based immunotherapies for cancer treatment. The company's revenue is generated through the development of targeted immunotherapies, including adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its product pipeline includes ACTengine candidates such as IMA201, IMA202, IMA203, and IMA204, targeting various solid tumors, as well as TCR Bispecifics candidates IMA401 and IMA402 for the treatment of solid tumors. Immatics N.V. also develops IMA101 and IMA301 for cancer treatment. The company has strategic collaborations with GlaxoSmithKline, MD Anderson Cancer Center, Celgene Switzerland, and Genmab A/S to develop novel therapies targeting multiple cancer indications.
